GTC Biotherapeutics, Inc. (NASDAQ: GTCB)

GTC Biotherapeutics, Inc. (NASDAQ: GTCB) is focused on developing, supplying, and commercializing therapeutic proteins created through transgenic animal technology. ATryn, the company’s recombinant human antithrombin, has received approval for use in Europe and is in the review process in the United States under a rolling Biologics License Application. The company’s intellectual property includes a patent in the United States for the production of therapeutic proteins in the milk of transgenic mammals. For further information, visit the Company’s web site at www.gtc-bio.com.